医药行业24Q3公募基金持仓分析

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [1]. Core Insights - As of Q3 2024, the proportion of pharmaceutical stocks in all public fund heavy holdings decreased to 8.92%, down by 0.49 percentage points from Q2 2024 [3]. - The total market value of pharmaceutical stocks held by public funds increased from 242.7 billion to 281.5 billion, representing a growth of 16% from Q2 to Q3 2024 [4]. - The top five segments by market value in Q3 2024 were: Chemical Preparations (77.3 billion, 27%), Medical Devices (61.3 billion, 22%), Medical R&D Outsourcing (41.7 billion, 15%), Traditional Chinese Medicine III (24.2 billion, 9%), and Medical Consumables (16.4 billion, 6%) [4]. Summary by Sections 1. 2024Q3 Pharmaceutical Stock Holdings Ratio - The pharmaceutical stock holding ratio among all public funds was 8.92%, a decrease from 9.41% in Q2 2024 [3]. 2. 2024Q3 Pharmaceutical Subsector Public Fund Holdings Market Value - The total market value of pharmaceutical stocks held by public funds rose to 281.5 billion, with notable increases in segments such as Chemical Preparations (+17 billion) and Medical R&D Outsourcing (+15 billion) [4][5]. - The segments that saw a decline included Offline Pharmacies (-0.3 billion) and Medical Devices (-2.3 billion) [4]. 3. 2024Q3 Public Fund Heavy Holdings - The top five stocks by the number of public fund holdings were: Heng Rui Medicine (573), Mai Rui Medical (453), Ke Lun Pharmaceutical (203), WuXi AppTec (190), and Ai Er Eye Hospital (156) [5][7]. - The stocks with the highest increase in the number of public fund holdings were Heng Rui Medicine (+188) and WuXi AppTec (+79) [5][7].